- Home
- ACRV vs CLYM Comparison
ACRV vs CLYM Comparison
Compare ACRV & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRV
- CLYM
- Stock Information
- Founded
- ACRV 2018
- CLYM 2018
- Country
- ACRV United States
- CLYM United States
- Employees
- ACRV N/A
- CLYM N/A
- Industry
- ACRV Medicinal Chemicals and Botanical Products
- CLYM
- Sector
- ACRV Health Care
- CLYM
- Exchange
- ACRV Nasdaq
- CLYM NYSE
- Market Cap
- ACRV 247.8M
- CLYM 242.8M
- IPO Year
- ACRV 2022
- CLYM 2021
- Fundamental
- Price
- ACRV $6.44
- CLYM $3.00
- Analyst Decision
- ACRV Strong Buy
- CLYM
- Analyst Count
- ACRV 5
- CLYM 0
- Target Price
- ACRV $22.40
- CLYM N/A
- AVG Volume (30 Days)
- ACRV 46.9K
- CLYM 317.4K
- Earning Date
- ACRV 11-13-2024
- CLYM 11-12-2024
- Dividend Yield
- ACRV N/A
- CLYM N/A
- EPS Growth
- ACRV N/A
- CLYM N/A
- EPS
- ACRV N/A
- CLYM N/A
- Revenue
- ACRV N/A
- CLYM N/A
- Revenue This Year
- ACRV N/A
- CLYM N/A
- Revenue Next Year
- ACRV N/A
- CLYM N/A
- P/E Ratio
- ACRV N/A
- CLYM N/A
- Revenue Growth
- ACRV N/A
- CLYM N/A
- 52 Week Low
- ACRV $3.19
- CLYM $2.35
- 52 Week High
- ACRV $11.90
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- ACRV 31.95
- CLYM N/A
- Support Level
- ACRV $6.11
- CLYM N/A
- Resistance Level
- ACRV $8.35
- CLYM N/A
- Average True Range (ATR)
- ACRV 0.48
- CLYM 0.00
- MACD
- ACRV -0.23
- CLYM 0.00
- Stochastic Oscillator
- ACRV 12.55
- CLYM 0.00
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.